Aims Inflammatory and immune activation and body wasting are important features of end-stage chronic heart failure. It is not known whether restoration of cardiac output by assist device implantation can improve these abnormalities.
Introduction
Key features of end-stage chronic heart failure are body wasting and inflammatory and immune activation. The origins of immune activation remain unclear, but may be related to body wasting, that is, cardiac cachexia [1, 2] , itself associated with a particularly poor prognosis [3] .
Possible explanations for immune activation include the heart as a source of cytokines, supported by the finding that explanted failing hearts exhibit tumour necrosis factor expression [4] . Transgenic mice with cardiac over-expression of tumour necrosis factor develop impaired cardiac function, congestive heart failure and die prematurely [5, 6] . Thus, if the heart is, indeed, the origin of immune activation, it may contribute to further deterioration in cardiac function. The potential stimulus to cardiac production of tumour necrosis factor is not clear.
Anker et al. have developed an alternative hypothesis, that immune activation may be secondary to bacterial endotoxin exposure, perhaps as a result of repeated episodes of bowel wall oedema and subsequent translocation of bacterial products across the intestinal wall [7] . In support of this hypothesis, circulating levels of endotoxin are higher in heart failure patients with oedema, and become lower with diuretic treatment [8] . We were interested to investigate what might happen to immune activation in a group of patients with very severe heart failure who had their central haemodynamic problem corrected by the implantation of a ventricular assist device. Device implantation is itself a potentially strongly immunogenic stimulus. We measured tumour necrosis factor and its soluble receptor, and CD14 as a measure of endotoxin-cell interaction [9] . In addition, we measured activated complement levels, and elastase as a measure of neutrophil activation [10, 11] . There is no treatment at present for cachexia in chronic heart failure patients that restores normal weight. To assess the global metabolic effects of left ventricular assist device implantation, we also studied body weight changes after surgery.
Methods
We studied 48 patients at a single site who had ventricular assist devices implanted for severe cardiac failure (all New York Heart Association class IV). The indication for device implantation was end-stage heart failure or cardiogenic shock in all cases. The underlying presumption in all cases was that the patient would die without further support whilst on maximal medical therapy. The aim for each patient was that device implantation would be a bridge to transplantation. The implantations were performed between November 1992 and June 1995.
The study was approved by the ethics Committee of the Berlin Charité Hospital. Many patients were unable to give consent for the blood testing, but a relative of the patient was asked to give consent where necessary.
An ELISA was used to measure both C3a (Progen Biotechnik GmbH, Heidelberg, Germany) and C5a (Behring Werke AG, Marburg, Germany), C3a and C5a being activated complement factors 3 and 5, respectively. Elastase was measured by a commercially available ELISA test (E. Merck AG, Darmstadt, Germany). CD14 was measured by an ELISA test kit with a sensitivity 1 ng . ml 1 (IBL, Hamburg, Germany). Test kits from R&D Systems (Minneapolis, MN, U.S.A.) were used to measure soluble tumour necrosis factor receptor 1 (sensitivity 25 pg . ml 1 ) and interleukin-6 (sensitivity 0·094 pg . ml 1 ). Total tumour necrosis factor (Medgenix, Fleurus, Belgium; lower limit of detectability 3·0 pg . ml 1 ) was also measured. The results from this test are not influenced by soluble tumour necrosis factor receptors.
Samples were taken, separated and frozen at 80 C for later analysis. Plasma levels of the cytokines were measured. The same sampling system was used for all patients. Samples were taken at the time of surgery (n=48), and in survivors at 1 week (n=46), 1 month (n=35) and 90 days (n=26) post-operation. Data for the cytokines measured were log transformed to achieve a normal distribution. We used Cox proportional hazard analysis with Kaplan-Meier plots to illustrate survival data. In those patients who survived at least 90 days (n=26), comparison between variables at different time slots was with a repeated measures analysis of variance, with post hoc analysis where appropriate. In order to compare data between the time slots for all subjects alive at that moment, repeated paired t-tests were used with statistical significance set at a probability of <0·01. For other statistical tests, a probability of <0·05 was taken to be statistically significant. Correlations were performed by the least squares methods. Data are presented as mean SD.
Results
Patient data at the time of surgery are shown in Table 1 . There were more patients with dilated cardiomyopathy than with ischaemic heart disease. All patients were on intravenous inotropic support at the time of implantation. The duration of heart failure before assist device implantation was 3·89 3·94 years (range 1 month to 13 years). Twenty-five patients had a left ventricular assist device (20 patients had a Novacor [12] , five a HeartMate TCI [13] ) and 23 a biventricular assist (the Berlin Heart [14] ). The devices were implanted with the patient on cardiopulmonary bypass. Heparin was antagonized fully with protamine after termination of extracorporeal circulation. Intravenous heparin was started 6 to 12 h after the operation in the absence of bleeding. Patients with the Berlin Heart and Novacor were later switched to coumadine and acetylsalicylic acid was added. Patients on TCI received only acetylsalicylic acid. The HeartMate TCI left ventricular assist device implantation is distinct from the other two devices in that its pumping chamber is made of titanium and has a rough inner surface allowing for generation of an inner surface lining [13] . The average age of the patients was 45·3 years (range 15·0-67·4 years). At operation, all patients were in the intensive care unit requiring inotropic support. Pulmonary artery pressure fell immediately after the operation from a mean of 35·3 1·1 mmHg to 25·1 0·8 (P<0·0001) (Fig. 1) . Mean systemic arterial pressure increased from 66·5 1·2 at operation to 78·3 1·3 at 1 week (P<0·0001). There was no difference between devices in the haemodynamic response (P>0·2).
The clinical outcomes are shown in Table 2 . The mean duration of ventricular assist support was 124 days (range 3-796). Note that five subjects had sufficient recovery of ventricular function for their assist devices to be explanted, with long-term survival. These survivors all had a dilated cardiomyopathy, but had the same average age (45·0 4·1 years), height (174 4 cm) and cytokine levels as the main group. They had a higher cardiac index at implantation (2·1 l . min 1 . m 2 ) than the main group, but ejection fraction and arterial pressures were the same. The survivors were heavier than the main group (85·2 3·4 kg vs 75·2 4·5: P=0·2). The survival for the group as a whole is shown in Fig. 2 .
The results for cytokine assays for all patients are shown in Table 3 and Fig. 3 . There were no differences between those who had a biventricular assist device implanted and those with a left ventricular assist. After device implantation, there was a significant initial fall in tumour necrosis factor concentration, with a gradual return to pre-implantation values. In order to remove the bias induced by considering patients who died before the later stages of follow-up, we also show the data in Fig. 4 for those patients who survived with ventricular assist support for 90 days (n=26). There was no substantial difference between the two sets of results. There was no difference in the measured cytokines at the time of 
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operation between those who died during the first year of follow-up and those who survived (n=12). In Cox survival analyses, levels of the measured cytokines at operation did not predict outcome. The rise in tumour necrosis factor at 90 days follow-up was not associated with an increase in signs of infection. There was no rise in white cell count during this period (indeed, the white count fell slightly during follow-up; Table 3 ), and there was no correlation between the white cell count and tumour necrosis factor at any time point. There was no interaction between the change in cytokine levels over time and clinical outcome (transplantation, death, survival).
There was no significant change in soluble tumour necrosis factor receptor type 1. There was a slight, but significant increase in soluble CD14 receptors over the time course of the study. Changes in elastase, interleukin-6 and C3a paralleled the changes in tumour necrosis factor , although the decline in these variables continued to the 40 day time point before beginning to rise again.
There was a reduction in body mass after the operation (79·6 2·6 kg pre-operatively; 73·2 2·4 at 1 month (n=35; P<0·001; Fig. 5 ), and 72·5 2·6 at 90 days). There was a similar reduction in body mass index from 24·9 0·8 kg . m 2 pre-operatively to 23·3 0·5 kg . m 2 at 1 month (P<0·001 vs baseline) and 23·0 0·8 kg . m 2 at 90 days (P>0·2 for the comparison with 1 month). This difference was more marked when the mass of the devices was subtracted from the patients' weight (72·4 14·3 kg at 1 month, 71·7 14·3 at 90 days). There was no relation between body mass index and duration of heart failure (R=0·03; P>0·5).
Survival analysis
Those patients who survived 90 days following the operation (n=26) were heavier at the time of operation than those who died (83·1 (15·3) kg vs 73·4 (10·5): P=0·008). Pre-operative body mass index predicted survival as a continuous variable (P=0·0053). Figure 6 shows survival in patients with a body mass index above and below 25 kg . m 2 , which was the cut off for the group of patients in the highest tertile for body mass index.
Of the cytokines measured at baseline, only tumour necrosis factor receptor-1 weakly predicted survival (P=0·02). Urea also predicted outcome (P=0·01). There was no effect from electrolytes, blood count variables or liver function on survival. There was no effect from sex, age or underlying cause of heart failure on outcome. Only body mass index was an independent predictor of survival. 
Correlation analysis
Correlations between variables are shown in Table 4 . There was a close relationship between elastase and C3a ( Fig. 7) . At the time of operation, there were no correlations between haemodynamic variables and any of the inflammatory indices measured. There was a close 
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relationship between urea and tumour necrosis factor receptor 1.
There was a very weak relationship between weight at operation and tumour necrosis factor receptor 1 (r= 0·34; P<0·05), and between weight and interleukin-6 (r= 0·37; P=0·02). There were no correlations between weight loss, expressed in absolute terms or as a proportion of initial weight, and change in cytokine level, expressed in absolute terms or as a proportion of initial level.
Discussion
We have studied cytokine responses to the implantation of a left ventricular assist device in patients with end-stage heart failure. Device implantation results in a temporary fall in tumour necrosis factor and interleukin-6, but these largely returned to preimplantation levels by 90 days follow-up. Although none of the cytokines we measured independently predicted outcome, there was a strong relationship between body mass at the time of operation and clinical outcome.
Elevated levels of tumour necrosis were first reported in 1990 by Levine et al. who studied heart failure patients with cachexia [1] . Many other immune cytokines have been reported to be elevated in chronic heart failure, such as interleukins 1 [15] , 2 [15, 16] , 6 [17] and 8 [18] , soluble tumour necrosis factor receptors [7, 19] , and leukocyte chemokines [20] . Associated with the immune activation is a generalized imbalance between anabolic and catabolic processes [2, 21, 22] , such that catabolism predominates [23] . There are two complementary explanations for the origin of these phenomena. One asserts that abnormal 
Results are shown for data at the time of operation (n=48). TNFR-1=tumour necrosis factor receptor type 1; TNF=tumour necrosis factor; sCD14=soluble CD14; C3a and C5a=activated complement factors 3 and 5, respectively; IL-6=interleukin-6; WCC=white cell count. 
Figure 7
The relationship between elastase and activated C3. =before operation; =1 week; =40 days; =90 days.
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haemodynamics are the source of inflammatory and immune activation [4] , and that chronic hypoxia may result in endothelial production of free radicals and consequently leukocyte activation [24] . The heart itself may be a source of immune activation by this hypothesis. A second asserts that immune activation is a consequence of exposure to exogenous antigen [7] . The clinical problem of end-stage heart failure can be tackled by heart transplantation, and increasingly by the implantation of ventricular assist devices, usually as a bridge to transplantation [25, 26] . Problems with devices include thromboembolic events and possible systemic inflammatory responses related to blood contact with artificial surfaces [27] . We have previously shown that the degree of complement activation is a function of the severity of cardiogenic shock prior to circulatory support, rather than an effect of surface activation [28] .
In the present study we sought to describe the pattern of inflammatory response to the implantation of a ventricular assist device. The device improves the haemodynamic deficit of severe chronic heart failure, but without removing the heart as a potential source of immune activation. In addition, it adds a potentially potent extra source of immune activation in the shape of an extensive foreign surface. However, if there is significant spillover from cardiac cytokine production, unloading the heart with an assist device should cause longterm reduction in peripheral cytokine levels in survivors.
Despite these potentially potent sources of additional inflammation, and the effects of major surgery, we have found an initial reduction in indices of inflammation as evidenced by a fall in levels of tumour necrosis factor , interleukin-6 and activated complement. These observations accord with previous work that suggested that left ventricular assist device implantation reduces the expression of myocardial tumour necrosis factor [29] . Assist device implantation can have a profoundly depressant effect on T-cell function lasting up to 3 months [30] . The fall in tumour necrosis factor seen with mechanical assist is in contrast to what is seen with medical therapy for acute episodes of decompensation of chronic heart failure where levels do not fall quickly [7, 31] . Why is there a gradual increase in indices of immune activation later during the course of the study? There is no sign that the patients are retaining fluid and becoming oedematous again. Equally, with the heart still supported by the assist device, it seems unlikely that the heart has started to secrete tumour necrosis factor . It may be that there is low grade sepsis that we have not detected clinically, or it may reflect immunosuppression induced by surgery and illness, that is then subsequently wearing off. Inflammatory and immune activation may be independent of haemodynamic and functional changes.
We found no fall in the levels of CD14 and soluble tumour necrosis factor receptor; indeed there was a slight rise in CD14 over the period of the study. CD14 is thought to be representative of longer term exposure to endotoxin. The temporary fall in tumour necrosis factor and interleukin-6 might be explained by a short-term reduction in ischaemia as a result of an increase in cardiac output. In the longer term, tumour necrosis factor increases again (and other inflammatory markers never change) because the pathophysiological process resulting in inflammation is not altered by assist device implantation, as suggested by the persisting CD14 level.
We considered the possibility that changes in plasma volume might influence cytokine levels, but we saw no change in haemoglobin or haematocrit (which was influenced by surgical management). Therefore we believe that plasma volume could only have had a minor influence. Nevertheless, the volume of distribution of cytokines in heart failure patients is not known. In view of the loss of weight in the first week after surgery, this may have influenced results: future studies will have to address this issue in detail.
Cardiopulmonary bypass circuits have been shown to be potent stimulants of an inflammatory response in the short-term [32, 33] , but we saw a fall in activated complement and elastase at 1 week. This is perhaps surprising in view of the pro-thrombotic stimulus represented by the support device. It might be that the stress of illness and surgery resulted in suppression of the immune response [34] . Nevertheless, complement levels were higher than seen in normal subjects (C3a <200 ng . ml 1 , C5a <500 ng . ml 1 ). Elastase was reduced to within the normal range (<85 g . ml 1 ). There is no currently available treatment specifically for increasing body weight in heart failure patients. Restoring cardiac output might have such an effect. We observed significant weight loss after the assist devices were implanted (6·5 kg, or 8·1% of body mass). This weight loss is probably due, at least in part, to reductions in body oedema, although we were not able specifically to test for this. It might be thought that greater pre-operative weight represents more fluid retention, and hence worse heart failure, but in this group of patients, a higher pre-operative weight conferred a better prognosis. This may reflect the known adverse effect of cachexia on prognosis [3] . The left ventricular assist device implantation did not seem to function as a specific anticachexia intervention, as suggested by the fact that there was a further (small) decline in body mass index by the 90 day follow-up.
Limitations
There is a possible confounder in the tumour necrosis factor data in that the administration of heparin can enhance tumour necrosis factor production by monocytes [35] . All our patients were still receiving heparin at the 1 week time point, suggesting that the intrinsic fall in tumour necrosis factor may be being under-estimated. Monocytes are the main site of tumour necrosis factor production and we have not measured differential white cell counts, nor have we measured left ventricular volumes, and cannot thus assess any effect that change in wall stress may have on immune activation.
Conclusions
Patients undergoing ventricular assist device implantation for severe congestive heart failure as a bridge to transplantation have evidence of inflammatory activation as demonstrated by raised levels of tumour necrosis factor and its receptor, activated complement and elastase and CD14. The levels of tumour necrosis factor , interleukin-6, C3a and elastase are all reduced by device implantation, although levels start to rise again between 1 week and 1 month after operation. In the short-term in this group of severely diseased patients, left ventricular assist device implantation has no anticachectic effect. Lower body mass index at the time of device implantation is a powerful predictor of poor outcome.
